Drug
Secukinumab S C
Secukinumab S C: highest development phase Post-Market, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Secukinumab s.c. injection NCT04638647 | Post-Market | Autoimmunity, Inflammation |
Latest
No recent events.
Follow Secukinumab S C on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.